↓ Skip to main content

The Notch Ligand Jagged1 as a Target for Anti-Tumor Therapy

Overview of attention for article published in Frontiers in oncology, January 2014
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (75th percentile)
  • High Attention Score compared to outputs of the same age and source (84th percentile)

Mentioned by

twitter
3 X users
wikipedia
1 Wikipedia page

Citations

dimensions_citation
167 Dimensions

Readers on

mendeley
168 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
The Notch Ligand Jagged1 as a Target for Anti-Tumor Therapy
Published in
Frontiers in oncology, January 2014
DOI 10.3389/fonc.2014.00254
Pubmed ID
Authors

Demin Li, Massimo Masiero, Alison H. Banham, Adrian L. Harris

Abstract

The Notch pathway is increasingly attracting attention as a source of therapeutic targets for cancer. Ligand-induced Notch signaling has been implicated in various aspects of cancer biology; as a consequence, pan-Notch inhibitors and therapeutic antibodies targeting one or more of the Notch receptors have been investigated for cancer therapy. Alternatively, Notch ligands provide attractive options for therapy in cancer treatment due to their more restricted expression and better-defined functions, as well as their low rate of mutations in cancer. One of the Notch ligands, Jagged1 (JAG1), is overexpressed in many cancer types, and plays an important role in several aspects of tumor biology. In fact, JAG1-stimulated Notch activation is directly implicated in tumor growth through maintaining cancer stem cell populations, promoting cell survival, inhibiting apoptosis, and driving cell proliferation and metastasis. In addition, JAG1 can indirectly affect cancer by influencing tumor microenvironment components such as tumor vasculature and immune cell infiltration. This article gives an overview of JAG1 and its role in tumor biology, and its potential as a therapeutic target.

Timeline

Login to access the full chart related to this output.

If you don’t have an account, click here to discover Explorer

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 168 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
United Kingdom 2 1%
Iran, Islamic Republic of 1 <1%
China 1 <1%
Spain 1 <1%
Japan 1 <1%
Unknown 162 96%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 39 23%
Student > Bachelor 25 15%
Student > Master 24 14%
Researcher 22 13%
Professor > Associate Professor 8 5%
Other 27 16%
Unknown 23 14%
Readers by discipline Count As %
Agricultural and Biological Sciences 45 27%
Biochemistry, Genetics and Molecular Biology 42 25%
Medicine and Dentistry 23 14%
Unspecified 6 4%
Pharmacology, Toxicology and Pharmaceutical Science 4 2%
Other 17 10%
Unknown 31 18%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 5. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 12 August 2015.
All research outputs
#7,205,295
of 25,374,647 outputs
Outputs from Frontiers in oncology
#2,461
of 22,416 outputs
Outputs of similar age
#78,576
of 319,280 outputs
Outputs of similar age from Frontiers in oncology
#8
of 51 outputs
Altmetric has tracked 25,374,647 research outputs across all sources so far. This one has received more attention than most of these and is in the 71st percentile.
So far Altmetric has tracked 22,416 research outputs from this source. They receive a mean Attention Score of 3.0. This one has done well, scoring higher than 88% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 319,280 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 75% of its contemporaries.
We're also able to compare this research output to 51 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 84% of its contemporaries.